World Investment Advisors Invests $286,000 in Bio-Rad Laboratories, Inc. (NYSE:BIO)

World Investment Advisors bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 1,174 shares of the medical research company's stock, valued at approximately $286,000.

Several other large investors have also added to or reduced their stakes in the business. Bank of America Corp DE raised its holdings in shares of Bio-Rad Laboratories by 705.9% in the 4th quarter. Bank of America Corp DE now owns 427,292 shares of the medical research company's stock worth $140,370,000 after purchasing an additional 374,269 shares during the period. Ariel Investments LLC grew its stake in Bio-Rad Laboratories by 48.0% in the 4th quarter. Ariel Investments LLC now owns 560,524 shares of the medical research company's stock valued at $184,138,000 after buying an additional 181,829 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Bio-Rad Laboratories by 22,131.7% during the 1st quarter. GAMMA Investing LLC now owns 147,841 shares of the medical research company's stock valued at $36,008,000 after purchasing an additional 147,176 shares in the last quarter. Norges Bank purchased a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at $41,644,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Bio-Rad Laboratories by 14.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 746,119 shares of the medical research company's stock valued at $245,106,000 after purchasing an additional 91,690 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Analysts Set New Price Targets

BIO has been the subject of a number of research analyst reports. Wells Fargo & Company dropped their price objective on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a report on Monday, June 9th. UBS Group lowered their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Citigroup lowered their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Royal Bank Of Canada lowered their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $324.25.

Bio-Rad Laboratories Stock Performance

BIO stock traded down $6.05 on Monday, hitting $250.92. The company had a trading volume of 242,436 shares, compared to its average volume of 335,652. The company has a current ratio of 5.99, a quick ratio of 4.43 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $387.99. The stock has a market cap of $6.83 billion, a price-to-earnings ratio of -3.29 and a beta of 0.95. The stock's 50-day simple moving average is $237.15 and its 200 day simple moving average is $268.72.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.81. The business had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The company's quarterly revenue was down 4.2% on a year-over-year basis. During the same period last year, the firm earned $2.30 earnings per share. As a group, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.